Short answer
Axsome Therapeutics, Inc. (AXSM) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $260M (up 51.9% year over year) with net income of −$13M.
Q3 2026 key financials · XBRL
- Revenue
- $260M
- +51.9% YoY · +18.9% QoQ
- Net income
- −$13M
- +72.7% YoY · +74.9% QoQ
- Operating margin
- -4.3%
- EPS (diluted)
- −$0.23
- +75.8% YoY · +76.8% QoQ
Source: XBRL data from the Axsome Therapeutics, Inc. (AXSM) Q3 2026 10-Q on SEC EDGAR. USD.
Axsome Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $259.7M, up from $171.0M YoY, driven by product sales of $250.0M
- AUVELITY best performer: sales $207.6M vs $136.1M YoY
- SYMBRAVO lowest sales: $3.9M vs $2.1M YoY
- Operating loss $11.1M vs $46.1M; operating margin -4.3% vs -27.0% YoY
- Nine-month operating cash use $63.1M vs $74.8M; financing provided $54.8M, including $19.5M equity proceeds
- Outlook: SG&A marginally higher through 2026, R&D moderately higher; cash expected to fund operations into cash-flow positivity
Risk Factors
- Regulatory risk: Canada Revenue Agency examination of 2024 and 2025 Canadian income tax returns remains ongoing
- Legal risk: Second SYMBRAVO patent infringement action against Apotex commenced August 31, 2026
- Operational risk: Limited contract manufacturers, sometimes only one supplier for products
- Financial risk: $70.0 million Revolver outstanding at September 30, 2026, repaid in October 2026
- Concentration risk: Majority of $313.9 million cash held by two financial institutions above insurance limits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axsome Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.